ABSTRACT − Manufacturing a multi-layered tablet such as Xatral XL ® is more complex and expensive than monolayeredtablets, but mono-layered tablets may have less favorable release properties depending on the pharmacodynamics and phar-macokinetics of the active ingredient. We therefore sought to develop a monolayer tablet with a similar dissolution profileto the commercial alfuzosin sustained-release triple layered tablet (Xatral XL ® ). We prepared four different mono-layeredalfuzosin tablets with different concentrations of hydroxypropyl methycellulose and PVP K-90. Fomulation III with alfu-zosion/ mg-stearate/ HPMC/ PVP K-90 (10/5/110/95 mg/tab) has a similar dissolution rate to Xatral XL ® , with a similarityfactor score of 81.4. However, the swelling and erosion rates of the two formulations were different, and NIR analysisshowed differences in the mechanisms of drug release. Thus, although formulation III and Xatral XL ® show similar dis-solution rates, the mechanisms of drug release are different.Key words